a Structure of 2-(5-mercapto-1,3,4-oxadiazol-2-yl)-N-propylbenzenesulphonamide (MOPBS). b MOPBS (1, 10, 50 and 100 mg/ kg) pretreatment reduced carrageenan-induced paw oedema. The paw thickness was measured after 4 h of carrageenan injection. c MOPBS (1, 10, 50 and 100 mg/kg) pretreatment inhibited carrageenaninduced mechanical hyperalgesia, d mechanical allodynia and e thermal hyperalgesia. The paw withdrawal effect was measured after 4 h of carrageenan injection The data are expressed as the mean ± SD (*) p < 0.01, (**) p < 0.001 and (***) p < 0.0001 show a significant difference from carrageenan-induced group. (###) denotes comparison of vehicle control group (normal group) and carrageenan-induced group with MOPBS-treated group
